» Articles » PMID: 5294178

Studies on Vaccination Against Bacillary Dysentery. 1. Immunization of Mice Against Experimental Shigella Infection

Overview
Specialty Public Health
Date 1965 Jan 1
PMID 5294178
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

In the course of a series of experiments begun in 1954 a number of different killed vaccines prepared from Shigella flexneri 1 and 2a serotypes were tested for their immunogenicity after intraperitoneal administration in mice followed by challenge with virulent organisms of the same serotype; some live vaccines were also tested intraperitoneally or orally.Maintenance of the mice on Freter's regimen proved a reliable method of rendering them susceptible to intestinal infection with streptomycin-resistant shigellae.Two killed vaccines conferred good protection against intracerebral challenge, but neither live nor killed vaccines administered intraperitoneally protected against oral infection of mice maintained on Freter's regimen. However, oral administration of live vaccine did confer significant protection against homologous oral challenge, the degree of protection depending on the dose of vaccine.

Citing Articles

From Kiyoshi Shiga to Present-Day Shigella Vaccines: A Historical Narrative Review.

Herrera C, Schmitt J, Chowdhry E, Riddle M Vaccines (Basel). 2022; 10(5).

PMID: 35632401 PMC: 9145194. DOI: 10.3390/vaccines10050645.


Shigella-Controlled Human Infection Models: Current and Future Perspectives.

Clarkson K, Porter C, Talaat K, Kapulu M, Chen W, Frenck Jr R Curr Top Microbiol Immunol. 2022; 445:257-313.

PMID: 35616717 PMC: 7616482. DOI: 10.1007/82_2021_248.


Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Levine M, Kotloff K, Barry E, Pasetti M, Sztein M Nat Rev Microbiol. 2007; 5(7):540-53.

PMID: 17558427 PMC: 3771495. DOI: 10.1038/nrmicro1662.


Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.

Kotloff K, Noriega F, Samandari T, Sztein M, Losonsky G, Nataro J Infect Immun. 2000; 68(3):1034-9.

PMID: 10678904 PMC: 97245. DOI: 10.1128/IAI.68.3.1034-1039.2000.


Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection.

Van De Verg L, Mallett C, Collins H, Larsen T, Hammack C, Hale T Infect Immun. 1995; 63(5):1947-54.

PMID: 7729907 PMC: 173248. DOI: 10.1128/iai.63.5.1947-1954.1995.


References
1.
Freter R . Experimental enteric Shigella and Vibrio infections in mice and guinea pigs. J Exp Med. 1956; 104(3):411-8. PMC: 2136576. DOI: 10.1084/jem.104.3.411. View

2.
Cooper G . Experimental shigellosis in mice. I. Chronic infection with Shigella dysenteriae type 2. Aust J Exp Biol Med Sci. 1959; 37:193-200. DOI: 10.1038/icb.1959.21. View

3.
Morgan W . Studies in immuno-chemistry: The isolation and properties of a specific antigenic substance from B. dysenteriae (Shiga). Biochem J. 1937; 31(11):2003-21. PMC: 1267174. DOI: 10.1042/bj0312003. View

4.
MEL D . [Up to date experiences in the production of an anti-dysentery vaccine. (Preliminary communication)]. Vojnosanit Pregl. 1962; 19:353-6. View

5.
Freter R, Gangarosa E . ORAL IMMUNIZATION AND PRODUCTION OF COPROANTIBODY IN HUMAN VOLUNTEERS. J Immunol. 1963; 91:724-9. View